AstraZeneca's motavizumab needs more study for RSV prevention, US panel says
This article was originally published in Scrip
Executive Summary
AstraZeneca's (MedImmune) motavizumab needs further clinical study before approval for respiratory syncytial virus (RSV) prophylaxis in high-risk children, the US FDA's outside advisors said on 2 June.